Skip to content
Open access

Noncoding regulatory mutations contribute to the aberrant gene expression profile of neuroblastomas

Sep 2026 · bioRxiv · 0 citations · 45 references
Biology

TL;DR

This study compared ASE profiles of 156 neuroblastoma patients with 220 adrenal gland tissues from the Genotype-Tissue Expression (GTEx) Project to identify 1,363 neuroblastoma-specific ASE genes, which were enriched for biological processes relevant to neuroblastoma pathogenesis including chromatin remodeling, protein ubiquitination, and sympathetic nervous system development.

Abstract

Comprehensive analyses of whole-genome and exome sequencing data from high-risk neuroblastoma tumors have identified relatively few recurrent and clinically actionable protein-coding driver mutations at initial diagnosis. This suggests that noncoding genetic variations that alter regulatory sequences and impact gene expression are important drivers of neuroblastoma tumorigenesis. Allele-specific expression (ASE), which quantifies differences in expression between the two alleles of a gene, is a powerful approach for identifying genes with altered dosage resulting from cis-regulatory variation. In this study, we compared ASE profiles of 156 neuroblastoma patients with 220 adrenal gland tissues from the Genotype-Tissue Expression (GTEx) Project to identify 1,363 neuroblastoma-specific ASE genes. We demonstrated that these genes were enriched for biological processes relevant to neuroblastoma pathogenesis including chromatin remodeling, protein ubiquitination, and sympathetic nervous system development, and were preferentially associated with the adrenergic transcriptional program. To elucidate the genetic mechanism underlying aberrant expression of neuroblastoma-specific ASE genes we integrated our ASE data with somatic copy number alterations (SCNA) and somatic mutation profiles. We observed that although many neuroblastoma specific ASE genes were associated with chromosomal gains and losses, a substantial subset was located within copy-number-neutral genomic regions. These genes showed significant enrichment for noncoding somatic single-nucleotide variants (SNVs) within intronic and distal intergenic neuroblastoma-specific open chromatin regions. Furthermore, functional analyses revealed that many of these SNVs disrupt transcription factor binding sites for GATA3, a core component of the regulatory circuitry that maintains the adrenergic identity of neuroblastoma cells, and neuroblastoma-specific ASE genes harboring such mutations were significantly more likely to belong to the GATA3 regulon than expected by chance. Together, our findings identify novel molecular targets of noncoding regulatory mutations in neuroblastoma and highlight the important yet underappreciated contribution of noncoding genetic variation to neuroblastoma tumorigenesis.

Read PDF

Similar papers

Open access Sep 2026

Genomic foundation model-derived disruption profiling links somatic mutations to cancer biology and clinical outcomes

Cancer genomics has concentrated on individual mutations, overlooking whether somatic mutations can accumulate to produce partial, gene-level disruption with biological and clinical consequences. Sequence-to-function models can quantify these effects directly from DNA sequence. Here, we use AlphaGenome and AlphaMissens...

A. Nayak, Travita Lee, V. Agarwal et al. · 0 citations
Open access Sep 2026

Recurrent deletions and regulatory disruption of the Y chromosome in cancer

High-coverage whole-genome sequencing, large-scale transcriptomics, and eQTL are used to map male cancer cell lines, revealing a region-specific LOY landscape with recurrent euchromatic deletions affecting protein-coding genes and non-coding elements and motivating validation in primary tumor cohorts.

Trini Nguyen, Aditi Kuchi, Hong-Yu Liu et al. · 0 citations
Open access Oct 2026

A gene-centric analysis of copy number variation reveals tumour suppressor modulation of cancer risk and novel associations with common diseases

Copy number variants (CNVs) are a significant source of genomic variation in humans. They can span large genomic regions that encompass whole genes and their flanking regions, having the potential to alter the number of functional copies in an individual. Typically, CNVs are analysed individually or combined into regio...

S. Matthews, Cathal Seoighe, Gregory L. Wheeler · 0 citations
Sep 2026

Abstract A027: Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer

It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.

M. Dorsch, Felix E. G. Beaudry, A. Baginska et al. · 0 citations
Open access Oct 2026

Functional identification of non-coding regulatory regions that drive breast and skin carcinogenesis.

Large-scale functional screens are developed and performed to identify non-coding regulatory elements whose mutations drive cancer development in non-transformed human breast epithelial cells and mouse models of breast and skin cancer.

Robin H. Oh, Kevin C. L. Cheng, Evgenija Serafimova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.